Morning All24 Jun 2019 06:03
Another one of those long nights, really odd, from sleeping 18 hours a day, been lucky to get an hours sleep here and there these past few weeks. And one thing for sure it is not Scancell that is to blame for that, far from it.............
For me today heralds in the beginning of another new period in our development and growth as a company. The first for me was the period where David Evans was reading the agenda of the AGM, the first one I attended must be back in 2013 in London now. I could say the second period began after he finished, lol, it went on for ages, it was painful, but the second period for me was when John Chiplin replaced Evans, and for all the criticism he has taken from so many, we have under him arrived at the third phase, with the addition of Vulpes to our share holders and IMHO a very impressive Martin Diggle as we move back into human trials.
I don"t think it takes too much imagination to look back in retrospect, and see the mess we were in when he joined the BOD, and I will always remember LD and RG at a Derby AGM trying to reassure us all that relationships between the BOD had never been stronger. So easy looking at everything in retrospect, and in doing so the timelines make sense now as to a large degree does the fall in the SP.
So in the next few days we begin the SCIB1/Keytruda trial, knowing that MOD1 is getting nearer every day to its early 2020 start, and SCIB2 under the competent guidance of CRUK behind that and hopefully a start by a further 6 month period. Are there many companies recently valued at just under £20m who will have three important trials running at the same time, not to mention the next candidates progress to trials, the Glycans/Mabs etc etc.?? I rather doubt it.
So lets have a good week and enjoy this share, it has been a long time coming.